ALL   

Do you routinely check IgG levels during therapy, if not indicated by a study protocol?

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...

Based on St. Judes, DFCI, and BFM data, COG has recently decreased the length of therapy for males with B-Cell ALL.  Can this be extrapolated to ...

Late relapse is > 36 months from diagnosis.  

With the new COG leukemia studies, it is difficult to interpret these results in the context of their clinical status and conventional MRD 

Patient's leukemia has both T and Myeloid lineages 

For example, if the patient was on dasatinib before relapse, would you consider other second generation or third generation TKIs?

Does acute leukemia sub-type affect your decision? 

Outcomes for these patients are dismal, so looking for any insight on how to optimize outcomes for these patients.

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?